[go: up one dir, main page]

WO2002095010A3 - Proteines secretees humaines - Google Patents

Proteines secretees humaines Download PDF

Info

Publication number
WO2002095010A3
WO2002095010A3 PCT/US2002/009785 US0209785W WO02095010A3 WO 2002095010 A3 WO2002095010 A3 WO 2002095010A3 US 0209785 W US0209785 W US 0209785W WO 02095010 A3 WO02095010 A3 WO 02095010A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
present
human secreted
polynucleotides
encompassed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/009785
Other languages
English (en)
Other versions
WO2002095010A2 (fr
Inventor
Craig A Rosen
Steven M Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to EP02759068A priority Critical patent/EP1404702A4/fr
Priority to AU2002324424A priority patent/AU2002324424A1/en
Priority to CA002441840A priority patent/CA2441840A1/fr
Publication of WO2002095010A2 publication Critical patent/WO2002095010A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002095010A3 publication Critical patent/WO2002095010A3/fr
Priority to US11/366,486 priority patent/US20060246483A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention se rapporte à des polypeptides sécrétés humains, et à des molécules d'acide nucléique isolées codant ces polypeptides, qui sont utiles pour le diagnostic et le traitement des maladies cardio-vasculaires et des troubles et/ou états associés à ces maladies. Font également l'objet de cette invention des anticorps qui se fixent à ces polypeptides, ainsi que des vecteurs, des cellules hôtes et des procédés de recombinaison et de synthèse permettant de produire ces polynucléotides, ces polypeptides et/ou ces anticorps. Cette invention concerne en outre des procédés de criblage pour identifier des agonistes et des antagonistes de ces polynucléotides et polypeptides, ainsi que des procédés et des compositions pour inhiber ou améliorer la production et les fonctions de ces polypeptides.
PCT/US2002/009785 1997-03-07 2002-03-19 Proteines secretees humaines Ceased WO2002095010A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02759068A EP1404702A4 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
AU2002324424A AU2002324424A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
CA002441840A CA2441840A1 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
US11/366,486 US20060246483A1 (en) 1997-03-07 2006-03-03 337 human secreted proteins

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US60/277,340 2001-03-21
US30617101P 2001-07-19 2001-07-19
US60/306,171 2001-07-19
US33128701P 2001-11-13 2001-11-13
US60/331,287 2001-11-13

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US09/981,876 Continuation-In-Part US7053190B2 (en) 1997-03-07 2001-10-19 Secreted protein HRGDF73
US10/100,683 Continuation-In-Part US7368531B2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US66435803A Continuation-In-Part 1997-03-07 2003-09-20

Publications (2)

Publication Number Publication Date
WO2002095010A2 WO2002095010A2 (fr) 2002-11-28
WO2002095010A3 true WO2002095010A3 (fr) 2004-02-12

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
PCT/US2002/008123 Ceased WO2002102993A2 (fr) 1997-03-07 2002-03-19 Proteines secretees par l'homme
PCT/US2002/008279 Ceased WO2002090526A2 (fr) 1997-03-07 2002-03-19 Proteines secretees par les humains
PCT/US2002/008277 Ceased WO2003038063A2 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
PCT/US2002/008124 Ceased WO2003004622A2 (fr) 1997-03-07 2002-03-19 Proteines humaines secretees
PCT/US2002/009785 Ceased WO2002095010A2 (fr) 1997-03-07 2002-03-19 Proteines secretees humaines
PCT/US2002/008276 Ceased WO2002076488A1 (fr) 1997-03-07 2002-03-19 Proteines humaines secretees
PCT/US2002/008278 Ceased WO2002102994A2 (fr) 1997-03-07 2002-03-19 Proteines secretees humaines

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PCT/US2002/008123 Ceased WO2002102993A2 (fr) 1997-03-07 2002-03-19 Proteines secretees par l'homme
PCT/US2002/008279 Ceased WO2002090526A2 (fr) 1997-03-07 2002-03-19 Proteines secretees par les humains
PCT/US2002/008277 Ceased WO2003038063A2 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
PCT/US2002/008124 Ceased WO2003004622A2 (fr) 1997-03-07 2002-03-19 Proteines humaines secretees

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2002/008276 Ceased WO2002076488A1 (fr) 1997-03-07 2002-03-19 Proteines humaines secretees
PCT/US2002/008278 Ceased WO2002102994A2 (fr) 1997-03-07 2002-03-19 Proteines secretees humaines

Country Status (4)

Country Link
EP (7) EP1414845A4 (fr)
AU (6) AU2002324424A1 (fr)
CA (7) CA2441702A1 (fr)
WO (7) WO2002102993A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319006B2 (en) 1998-06-01 2008-01-15 Genentech, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US8940310B2 (en) 2010-06-16 2015-01-27 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
US8962579B2 (en) 2007-10-26 2015-02-24 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
US9593167B2 (en) 2006-10-27 2017-03-14 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US9617346B2 (en) 2004-04-22 2017-04-11 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002546A1 (fr) 1997-07-08 1999-01-21 Human Genome Sciences, Inc. 123 proteines humaines secretees
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6329503B1 (en) 1998-06-01 2001-12-11 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
AU2507700A (en) 1999-01-15 2000-08-01 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US20060073150A1 (en) 2001-09-06 2006-04-06 Mary Faris Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7335731B2 (en) 2000-07-25 2008-02-26 Genentech, Inc. PRO4332 polypeptides
EP1666490A3 (fr) * 2000-07-25 2006-11-02 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
WO2002048370A2 (fr) 2000-10-31 2002-06-20 Diadexus, Inc. Compositions et methodes associees a des genes et a des proteines specifiques du colon
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030119112A1 (en) 2001-06-20 2003-06-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP1439235A4 (fr) 2001-10-12 2006-01-18 Astellas Pharma Inc Methode de criblage d'inhibiteur de mort cellulaire
SI1997512T1 (sl) 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Postopki za zdravljenje stanj, povezanih s TWEAK-om
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (fr) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire
ES2339710T5 (es) 2003-09-23 2017-10-05 University Of North Carolina At Chapel Hill Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K
DK2272951T3 (da) * 2003-10-14 2014-10-13 Baxter Int VKORC1 (vitamin-K-epoxid-tilbageførings-polypeptid), et terapeutisk mål for coumarin og derivater deraf
WO2005076003A2 (fr) * 2004-02-03 2005-08-18 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour des maladies associes a la glutamate carboxypeptidase (pgcp) plasmatique
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
SI1794174T1 (sl) 2004-09-01 2012-09-28 Dynavax Tech Corp Postopki in sestavki za inhibiranje prirojenih imunskih odzivov in avtoimunosti
WO2006026808A1 (fr) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Methode de diagnostic et/ou de prediction du developpement d'une affection allergique
WO2006026807A1 (fr) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Agents pour le traitement ou la prevention d'une affection allergique
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
DK1853700T3 (da) 2005-02-28 2013-01-07 Baxter Int Rekombinant co-ekspression af vitamin-k-epoxid-reduktase-underenhed 1 til forbedring af vitamin-k-afhængig proteinekspression
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
CA2607697C (fr) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Traitement et evaluation des troubles inflammatoires
WO2006138219A2 (fr) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Procedes d'evaluation de patients
GB2470843B (en) * 2005-09-01 2011-04-13 Florey Howard Inst Models and methods for the assessment of potential therapeutic agents for the modulation of NDFIP1-NEDD4 interactions
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
JP5588175B2 (ja) 2006-11-07 2014-09-10 メルク・シャープ・アンド・ドーム・コーポレーション Ｐｃｓｋ９のアンタゴニスト
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EP2142217B1 (fr) * 2007-03-27 2014-11-05 Merck Sharp & Dohme Corp. Procédé de détection de pcsk9 secrétée, autogénérée
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP3536336A1 (fr) * 2007-11-30 2019-09-11 Siemens Healthcare Diagnostics Inc. Fragments de récepteur de l'adiponectine et procédés d'utilisation
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
WO2010068526A1 (fr) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Immunodosage de pcsk9
IN2012DN03824A (fr) 2009-10-30 2015-08-28 Merck Sharp & Dohme
US8802827B2 (en) 2009-10-30 2014-08-12 Merck Sharp & Dohme Corp. AX1 PCSK9 antagonists
CA2810928A1 (fr) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Analogues nucleotidiques substitues
EP2655607A4 (fr) 2010-12-21 2014-05-14 Univ North Carolina Procédés et compositions pour la production de protéines actives dépendantes de la vitamine k
CA2860234A1 (fr) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Analogues de nucleotide phosphorothioate substitue
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
GB2572918B (en) 2016-12-23 2023-02-15 Harvard College Gene editing of PCSK9
EP3642383B1 (fr) 2017-06-22 2022-12-21 The Procter & Gamble Company Films comprenant une couche hydrosoluble et un revêtement inorganique déposé en phase vapeur
US11192139B2 (en) 2017-06-22 2021-12-07 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited organic coating
BR112022020407A2 (pt) 2020-04-09 2023-05-02 Verve Therapeutics Inc Edição base do pcsk9 e métodos de uso do mesmo para tratamento de doenças

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
WO2002026931A2 (fr) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 proteines humaines secretees
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides
CA2333917A1 (fr) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 proteines humaines secretees

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE USPATFUL [online] 1999, RUBEN ET AL.: "64 Human secreted proteins", XP002968182, accession no. STN Database accession no. 2003:72168 *
See also references of EP1404702A4 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319006B2 (en) 1998-06-01 2008-01-15 Genentech, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US9617346B2 (en) 2004-04-22 2017-04-11 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US10597463B2 (en) 2004-04-22 2020-03-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11401347B2 (en) 2004-04-22 2022-08-02 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US9593167B2 (en) 2006-10-27 2017-03-14 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8962579B2 (en) 2007-10-26 2015-02-24 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
US9476053B2 (en) 2007-10-26 2016-10-25 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
US8940310B2 (en) 2010-06-16 2015-01-27 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US11685790B2 (en) 2017-04-03 2023-06-27 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US12129306B2 (en) 2017-04-03 2024-10-29 Hoffman-La Roche Inc. Antibodies binding to STEAP-1

Also Published As

Publication number Publication date
AU2002320013A1 (en) 2002-11-18
WO2002090526A3 (fr) 2003-10-30
EP1404702A4 (fr) 2009-07-08
CA2441416A1 (fr) 2003-01-16
EP1404702A2 (fr) 2004-04-07
AU2002354719A1 (en) 2003-01-21
WO2003038063A2 (fr) 2003-05-08
EP1423134A2 (fr) 2004-06-02
WO2002102994A2 (fr) 2002-12-27
WO2003004622A2 (fr) 2003-01-16
AU2002324424A1 (en) 2002-12-03
CA2441417A1 (fr) 2002-11-14
WO2002102993A2 (fr) 2002-12-27
EP1414845A2 (fr) 2004-05-06
EP1390390A4 (fr) 2009-07-08
AU2002332391A1 (en) 2003-01-02
EP1390390A2 (fr) 2004-02-25
CA2441397A1 (fr) 2002-10-03
EP1381622A2 (fr) 2004-01-21
WO2002095010A2 (fr) 2002-11-28
WO2002102993A3 (fr) 2004-03-25
AU2002326293A1 (en) 2003-01-02
WO2003004622A3 (fr) 2004-02-19
WO2002076488A1 (fr) 2002-10-03
CA2441840A1 (fr) 2002-11-28
AU2002363296A1 (en) 2003-05-12
EP1379132A2 (fr) 2004-01-14
EP1379264A1 (fr) 2004-01-14
WO2002102994A3 (fr) 2003-07-24
CA2441755A1 (fr) 2003-05-08
EP1379132A4 (fr) 2009-07-01
CA2441832A1 (fr) 2002-12-27
WO2003038063A3 (fr) 2003-12-11
EP1414845A4 (fr) 2009-07-08
WO2002090526A2 (fr) 2002-11-14
CA2441702A1 (fr) 2002-12-27
EP1379264A4 (fr) 2009-07-08

Similar Documents

Publication Publication Date Title
WO2002095010A3 (fr) Proteines secretees humaines
WO2003004623A3 (fr) Proteines humaines secretees
WO2001055311A8 (fr) Acides nucleiques, proteines et anticorps
WO2001090304A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055306A3 (fr) Acides nucleiques, proteines, et anticorps
WO2001055326A3 (fr) Acides nucleiques, proteines et anticorps
WO2004042000A3 (fr) 157 proteines secretees humaines
WO2001055168A8 (fr) Acides nucleiques, proteines, et anticorps
WO2002072763A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055167A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055162A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055305A3 (fr) Acides nucleiques, proteines, et anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2441840

Country of ref document: CA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002759068

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002759068

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP